{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T19:02:27Z","timestamp":1763665347234,"version":"build-2065373602"},"reference-count":47,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The advent of tyrosine kinase inhibitors (TKIs) blocking BCR-ABL activity has revolutionized the therapeutic management of patients with chronic myeloid leukemia (CML). Adverse cutaneous reactions (ACRs) are common nonhematologic adverse events associated with the use of BCR-ABL TKIs. A characteristic pattern of eruption resembling keratosis pilaris (KP) has been described in patients treated with these drugs, especially nilotinib and dasatinib. The pathogenesis of this ACR is still unknown. This type of reaction appears to be uncommon with imatinib. Here, we report the case of an elderly patient with an asymptomatic KP-like eruption, which appeared one month after starting treatment with imatinib for CML. The case presentation is accompanied by a review of similar reactions in patients with CML treated with BCR-ABL inhibitors, attempting to make an excursus on the molecular targets of such drugs and possible mechanisms underlying this ACR.<\/jats:p>","DOI":"10.3390\/jcm13010032","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T07:20:31Z","timestamp":1703056831000},"page":"32","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5718-7003","authenticated-orcid":false,"given":"Francesca","family":"Ambrogio","sequence":"first","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melita Anna","family":"Poli","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Lospalluti","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0860-3044","authenticated-orcid":false,"given":"Teresa","family":"Lettini","sequence":"additional","affiliation":[{"name":"Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Cassano","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology Private Practice, 76121 Barletta, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gino Antonio","family":"Vena","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology Private Practice, 76121 Barletta, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4792-3545","authenticated-orcid":false,"given":"Giuseppe","family":"Ingravallo","sequence":"additional","affiliation":[{"name":"Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0325-4316","authenticated-orcid":false,"given":"Gerardo","family":"Cazzato","sequence":"additional","affiliation":[{"name":"Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Foti","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12185-022-03510-w","article-title":"Genetic landscape of chronic myeloid leukemia","volume":"117","author":"Ochi","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100825","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s12185-021-03126-6","article-title":"Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"113","author":"Lee","year":"2021","journal-title":"Int. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.3816\/CLM.2008.s.002","article-title":"Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: Focus on dosing schedules","volume":"8","author":"Jabbour","year":"2008","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.leukres.2011.09.018","article-title":"What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?","volume":"36","author":"Deininger","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","article-title":"Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia","volume":"53","author":"Steegmann","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2009.111","article-title":"Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"23","author":"Giles","year":"2009","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/10428190801896103","article-title":"Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib","volume":"49","author":"Hantschel","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8300","DOI":"10.1111\/jcmm.16782","article-title":"Anti-growth and pro-apoptotic effects of dasatinib on human oral cancer cells through multi-targeted mechanisms","volume":"25","author":"Park","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5045\/br.2021.2021117","article-title":"A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities","volume":"56","author":"Nekoukar","year":"2021","journal-title":"Blood Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40487-015-0010-y","article-title":"Bosutinib for Chronic Myeloid Leukemia","volume":"3","author":"Breccia","year":"2015","journal-title":"Rare Cancers Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"106156","DOI":"10.1016\/j.phrs.2022.106156","article-title":"Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia","volume":"178","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zeng, P., and Schmaier, A. (2020). Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186556"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gao, Y., Ding, Y., Tai, X.R., Zhang, C., and Wang, D. (2023). Ponatinib: An update on its drug targets, therapeutic potential and safety. Biochim. Biophys. Acta Rev. Cancer, 1878.","DOI":"10.1016\/j.bbcan.2023.188949"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2217\/fon-2022-1008","article-title":"Rash with different types of BCR-ABL inhibitors in chronic myelogenous leukemia: A systematic review and meta-analysis","volume":"19","author":"Li","year":"2023","journal-title":"Future Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1529-8019.2011.01431.x","article-title":"Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib","volume":"24","author":"Stemmer","year":"2011","journal-title":"Dermatol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/jdv.12172","article-title":"Imatinib, dasatinib and nilotinib: A review of adverse cutaneous reactions with emphasis on our clinical experience","volume":"27","author":"Brazzelli","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.clml.2017.07.005","article-title":"Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies","volume":"17","author":"Ransohoff","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/ejh.12052","article-title":"Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: Meta-analysis and clinical characterization","volume":"90","author":"Drucker","year":"2013","journal-title":"Eur. J. Haematol"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jaad.2013.07.025","article-title":"Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia","volume":"69","author":"Delgado","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000437383","article-title":"Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia","volume":"232","author":"Patel","year":"2016","journal-title":"Dermatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/bjd.13692","article-title":"Ponatinib-induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities","volume":"173","author":"Alloo","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40264-020-00907-6","article-title":"Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review","volume":"43","author":"Vastarella","year":"2020","journal-title":"Drug Saf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023\u2014Common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/jdv.17081","article-title":"Trichodysplasia spinulosa: A comprehensive review of the disease and its treatment","volume":"35","author":"Curman","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/cup.14002","article-title":"Spiky\/keratosis-pilaris-like early follicular mycosis fungoides: A clinicopathologic study of 20 cases with extended follow-up","volume":"48","author":"Tomasini","year":"2021","journal-title":"J. Cutan. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/DAD.0b013e31828cf3b7","article-title":"Perforating folliculitis in a patient treated with nilotinib: A further evidence of C-kit involvement","volume":"36","author":"Steegmann","year":"2014","journal-title":"Am. J. Dermatopathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/cup.12715","article-title":"A case of scurvy associated with nilotinib","volume":"43","author":"Oak","year":"2016","journal-title":"J. Cutan. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5070\/D32510045822","article-title":"Follicular spicules of multiple myeloma","volume":"25","author":"Smith","year":"2019","journal-title":"Dermatol. Online J."},{"key":"ref_33","first-page":"217","article-title":"Keratosis pilaris: An update and approach to management","volume":"158","author":"Kodali","year":"2023","journal-title":"Ital. J. Dermatol. Venerol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40257-018-0368-3","article-title":"Keratosis Pilaris and its Subtypes: Associations, New Molecular and Pharmacologic Etiologies, and Therapeutic Options","volume":"19","author":"Wang","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/1346-8138.13336","article-title":"Generalized keratosis pilaris-like eruptions in a chronic myelogenous leukemia patient treated with nilotinib","volume":"43","author":"Shimizu","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000445676","article-title":"Nilotinib-Induced Keratosis Pilaris","volume":"8","author":"Leong","year":"2016","journal-title":"Case Rep. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5070\/D3228032159","article-title":"Nilontinib induced keratosis pilaris atrophicans","volume":"22","author":"Khetarpal","year":"2016","journal-title":"Dermatol. Online J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/ijt.ijt_1_17","article-title":"Nilotinib-induced Keratosis Pilaris Associated with Alopecia Areata and Eyebrow Thinning","volume":"9","author":"Tawil","year":"2017","journal-title":"Int. J. Trichology."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/pde.14267","article-title":"Keratosis pilaris-like eruption secondary to nilotinib in a child","volume":"37","author":"Feito","year":"2020","journal-title":"Pediatr. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e14579","DOI":"10.1111\/dth.14579","article-title":"Nilotinib-induced keratosis pilaris associated with cicatricial alopecia resembling frontal fibrosing alopecia","volume":"34","author":"Frioui","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"330","DOI":"10.4103\/ijp.IJP_553_20","article-title":"Nilotinib-induced generalized keratosis pilaris: Report of a rare case","volume":"53","author":"Kowe","year":"2021","journal-title":"Indian. J. Pharmacol."},{"key":"ref_42","first-page":"47","article-title":"Keratosis pilaris-like eruption induced by nilotinib","volume":"156","year":"2021","journal-title":"Ital. J. Dermatol. Venerol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(12)70413-8","article-title":"Cutaneous toxicities of RAF inhibitors","volume":"14","author":"Anforth","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Rinderknecht, J.D., Goldinger, S.M., Rozati, S., Kamarashev, J., Kerl, K., French, L.E., Dummer, R., and Belloni, B. (2013). RASopathic skin eruptions during vemurafenib therapy. PLoS ONE, 8.","DOI":"10.1371\/annotation\/d884b668-04f7-4ae6-96a3-a199df5b43be"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccr.2011.11.004","article-title":"Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia","volume":"20","author":"Packer","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_46","first-page":"1410","article-title":"A case of new onset keratosis pilaris after discontinuation of erlotinib","volume":"13","author":"Okereke","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2009.02.004","article-title":"Array of cutaneous adverse effects associated with sorafenib","volume":"61","author":"Kong","year":"2009","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/1\/32\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:42:06Z","timestamp":1760132526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/1\/32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["jcm13010032"],"URL":"https:\/\/doi.org\/10.3390\/jcm13010032","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2023,12,20]]}}}